Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients

被引：0
|
作者：
Braunstahl, Gert-Jan [1 ]
Deenstra, Marco [2 ]
Canvin, Janice [3 ]
Georgiou, Panos [3 ]
Peachey, Guy [3 ]
Chen, Chien-Wei [4 ]
机构：
[1] St Franciscus Gasthuis, Dept Pulm Med, Rotterdam, Netherlands
[2] Flevoziekenhuis, Dept Pulmonol, Almere, Netherlands
[3] Novartis Pharmaceut UK Ltd, Crit Care, Horsham, W Sussex, England
[4] Novartis Pharmaceut, Crit Care, E Hanover, NJ USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2012年 / 40卷
关键词：
Asthma; -; management; Pharmacology; Treatments;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2649
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Omalizumab in the management of patients with allergic (IgE-mediated) asthma
    Sandstrom, Thomas
    [J]. JOURNAL OF ASTHMA AND ALLERGY, 2009, 2 : 49 - 62
  • [2] IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy
    Humbert, Marc
    Bousquet, Jean
    Bachert, Claus
    Palomares, Oscar
    Pfister, Pascal
    Kottakis, Ioannis
    Jaumont, Xavier
    Thomsen, Simon Francis
    Papadopoulos, Nikolaos G.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (05): : 1418 - 1429
  • [3] Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma
    Milgrom, Henry
    Fowler-Taylor, Angel
    Vidaurre, Carlos Fernandez
    Jayawardene, Sumedha
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (01) : 163 - 169
  • [4] Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients
    Siergiejko, Zenon
    Swiebocka, Ewa
    Smith, Nicola
    Peckitt, Clare
    Leo, Jo
    Peachey, Guy
    Maykut, Robert
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (11) : 2223 - 2228
  • [5] Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
    Bousquet, J.
    Siergiejko, Z.
    Swiebocka, E.
    Humbert, M.
    Rabe, K. F.
    Smith, N.
    Leo, J.
    Peckitt, C.
    Maykut, R.
    Peachey, G.
    [J]. ALLERGY, 2011, 66 (05) : 671 - 678
  • [6] Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
    Kulus, M.
    Hebert, J.
    Garcia, E.
    Taylor, A. Fowler
    Vidaurre, C. Fernandez
    Blogg, M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1285 - 1293
  • [7] Omalizumab Improves Patient-Reported Outcomes In Patients With Allergic (IgE-mediated) Asthma
    Yang, W. H.
    Georgiou, P.
    Canvin, J.
    Chen, C.
    Peachey, G.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB147 - AB147
  • [8] Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE
    Lowe, Philip J.
    Renard, Didier
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 306 - 320
  • [9] Effect of Omalizumab on asthma control and quality of life in patients with moderate-severe persistent IgE-Mediated asthma and allergy to house dust mite
    Maykut, R.
    Massanari, M.
    Kianifard, F.
    Zeldin, R.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S157 - S157
  • [10] Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
    Lanier, Bob
    Bridges, Tracy
    Kulus, Marek
    Taylor, Angel Fowler
    Berhane, Indrias
    Vidaurre, Carlos Fernandez
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (06) : 1210 - 1216
12345